bluuebunny/crossref_metadata_2025_split huggingface dataset:
A Novel One‐Pot Reaction of Heterocyclic Ketene Aminals: Synthesis of a Small Library of Tetrahydropyridinone‐Fused 1,3‐Diazaheterocycles.
Authors: Yu Chu‐Yi , Yang Peng‐Hui , Zhao Mei‐Xin , Huang Zhi‐Tang 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Recyclization of Intermediates in an Enamine Rearrangement of a Pyrimidinium Salt When Treated with Isoniazide.
Authors: Danagulyan G. G. , Tadevosyan D. A. 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Efficient Access to Novel Mono‐ and Disubstituted Pyrido[3,2‐d]pyrimidines.
Authors: Tikad Abdellatif , Routier Sylvain , Akssira Mohamed , Leger Jean‐Michel , Jarry Christian , Guillaumet Gerald 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Synthesis and in vitro Anticancer and Antimicrobial Evaluation of Some Novel Quinoxalines Derived from 3‐Phenylquinoxaline‐2(1H)‐thione.
Authors: El‐Hawash Soad A. M. , Wahab Abeer E. Abdel 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Synthesis of Furo‐salicylanilides and Their Heterocyclic Derivatives with Anticipated Molluscicidal Activity.
Authors: Hassan Ghaneya Sayed , Hegazy Gehan Hegazy , Safwat Hany Mohamed 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Reaction of 2,3,5,10b‐Tetrahydrooxazolo[3,2‐c][1,3]benzoxazines with Chlorotrimethylsilane.
Authors: Kukharev B. F. , Stankevich V. K. , Klimenko G. R. , Bayandin V. V. , Kukhareva V. A. 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
A Highly Selective, Organocatalytic Route to Chiral 1,2‐Oxazines from Ketones.
Authors: Kumarn Sirirat , Shaw David M. , Ley Steven V. 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Synthesis of Polyether Cyclophanes Through Rhodium‐Catalyzed Cross‐Alkyne Cyclotrimerization.
Authors: Tanaka Ken , Sagae Hiromi , Toyoda Kazuki , Noguchi Keiichi 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Synthesis of Novel Salicylaldimine Schiff Bases with a Pendant Benzo‐10‐aza‐15‐crown.
Authors: Li Jianzhang , Yan Jie , Wei Xingyao , Zhou Bo , Qin Sheng‐ying 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
First Iodocyclization of β‐Allenic Phosphonates: A Novel Synthesis of α‐Difluoromethylenephostones.
Authors: Lin Yun , Liu Jin‐Tao 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Hydrophosphanation of Phenolic Aldehydes as Facile Synthetic Approach to Catechol‐Functionalized Phosphane Oxides and Phosphanes.
Authors: Chikkali Samir , Gudat Dietrich 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
A Convenient Synthesis of Aryl Ferrocenylethynyl Ketones and 2‐Ferrocenyl‐4H‐chromen‐4‐ones via Palladium‐Catalyzed Carbonylation Coupling.
Authors: Ma Wenbing , Li Xiaolong , Yang Jingmu , Liu Zenglu , Chen Baohua , Pan Xinfu 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Enantioselective Synthesis of α‐Terpineol and Nephthenol by Intramolecular Acyloxazolidinone Enolate Alkylations.
Authors: Jin Yinghua , Coates Robert M. 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
A General Route to Protected Quaternary α‐Amino Acids from β‐Amino Alcohols via a Stereocontrolled Radical Approach.
Authors: Wood Mark E. , Penny Mark J. , Steere Jenny S. , Horton Peter N. , Light Mark E. , Hursthouse Michael B. 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Preparation of a Fluorous Protecting Group and Its Application to the Chemoenzymatic Synthesis of Sialidase Inhibitor.
Authors: Ikeda Kiyoshi , Mori Hitomi , Sato Masayuki 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
A Biomimetic Synthesis of the Indolo[3,2‐j]phenanthridine Alkaloid, Calothrixin B.
Authors: Yamabuki Akira , Fujinawa Hikohito , Choshi Tominari , Tohyama Shigeo , Matsumoto Kohji , Ohmura Kana , Nobuhiro Junko , Hibino Satoshi 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Electrophilic Substitution Reactions of Indole Alkaloids with α,β‐Unsaturated Carbonyl Compounds in the Presence of K10 Montmorillonite.
Authors: Sarioez Oe. , Abdullah M. I. 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Unusual Reactivity of α‐Aminopapaverine.
Authors: Krivorotov D. V. , Vorob'ev M. V. , Polukeev V. A. , Petrov M. L. , Glibin E. N. , Didenko A. V. 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Synthesis of the Ester Side Chain of Some Potently Antileukemic Harringtonia Alkaloids from Chiral Citrates.
Authors: Ancliff Rachael A. , Russell Andrew T. , Sanderson Adam J. 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Total Synthesis of the Marine Natural Product (‐)‐Clavosolide A: Showcase for the Petasis—Ferrier Union/Rearrangement Tactic.
Authors: Smith Amos B. III , Simov Vladimir 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Unsupervised 3D Ring Template Searching as an Ideas Generator for Scaffold Hopping: Use of the LAMDA, RigFit, and Field‐Based Similarity Search (FBSS) Methods.
Authors: Bohl Martin , Loeprecht Bjoern , Wendt Bernd , Heritage Trevor , Richmond Nicola J. , Willett Peter 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Noise Reduction Method for Molecular Interaction Energy: Application to in Silico Drug Screening and in Silico Target Protein Screening.
Authors: Fukunishi Yoshifumi , Kubota Satoru , Nakamura Haruki 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Construction of Carbon Frameworks Through β‐Carbon Elimination Mediated by Transition Metals
Authors: Murakami Masahiro , Makino Masaomi , Ashida Shinji , Matsuda Takanori 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Five‐Membered Ring Systems with N and S (Se) Atoms
Authors: Wu Yong‐Jin , Velaparthi Upender , Yang Bingwei V. 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Prions and Transmissible Spongiform Encephalopathy (TSE) Chemotherapeutics: A Common Mechanism for anti‐TSE Compounds?
Authors: Caughey B. , Caughey W. S. , Kocisko D. A. , Lee K. S. , Silveira J. R. , Morrey J. D. 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Conformational Change and Assembly Through Edge β Strands in Transthyretin an Other Amyloid Proteins
Authors: Laidman Janel , Forse G. Jason , Yeates Todd O. 
Published: November 2006

AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinoma
Authors: Lal Geeta , Padmanabha Lakshmi , Smith Brian J. , Nicholson Rachael M. , Howe James R. , O'Dorisio M. Sue , Domann Frederick E. 
Published: November 2006

AbstractBACKGROUND.Allelotype studies have suggested that chromosome 1p is frequently lost in thyroid cancers, thus suggesting that there is an important tumor suppressor at this location. RIZ1 (PRDM2), located on 1p36, is a recently described tumor suppressor gene and is a member of the protein methyltransferase superfamily. RIZ1 expression is lost in a variety of tumors, primarily by means of epigenetic mechanisms that involve promoter hypermethylation.METHODS.RIZ1 expression was examined in a panel of thyroid tumor cell lines and primary thyroid tissues (14 normal, 19 benign, and 31 cancerous) by using real‐time polymerase chain reaction (PCR). Methylation status of the RIZ1 promoter was studied using bisulfite sequencing and methylation‐specific PCR.RESULTS.The authors demonstrated that RIZ1 expression is lost in thyroid tumor cell lines and is also significantly reduced in thyroid carcinomas, when compared with normal thyroid tissues (P < .0001) and benign tumors (P = .0003). The current study results also showed that loss of RIZ1 is mediated by aberrant cytosine methylation of the RIZ1 promoter. One hundred percent of carcinomas were methylated, compared with 33% of normal thyroid tissues (P = .001). RIZ1 mRNA expression was significantly higher (P = .02) in unmethylated (1.22 ± 1.2, mean ± standard deviation [SD]), compared with methylated tissues (0.37 ± 0.42, mean ± SD). Last, treatment with a DNA methyltransferase inhibitor led to reactivation of RIZ1 expression in cell lines that had negligible RIZ1 expression at baseline.CONCLUSIONS.The current study suggested an important role for RIZ1 expression in thyroid tumorigenesis and identified a potential novel therapeutic target for tumors unresponsive to other therapies. Cancer 2006. © 2006 American Cancer Society.
Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer
Authors: Ardizzoni Andrea , Cafferata Mara A. , Tiseo Marcello , Filiberti Rosangela , Marroni Paola , Grossi Francesco , Paganuzzi Michela 
Published: November 2006

AbstractBACKGROUND.The authors assessed the predictive and prognostic role of decline in the serum levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21‐1) during chemotherapy in patients with advanced nonsmall cell lung cancer (NSCLC).METHODS.Changes in serum levels of CEA and CYFRA 21‐1 during first‐line, conventional chemotherapy were studied prospectively with an immunometric assay at baseline and every 2 courses in 117 patients with advanced NSCLC. Data were correlated with radiologic objective response (OR) and survival.RESULTS.One hundred seven patients were evaluable for radiologic and serologic response assessment after 2 chemotherapy courses. The radiologic OR rate was 44% overall. The CEA and CYFRA 21‐1 responses (≥20% reduction over baseline level; assessed after the second course of chemotherapy) were 38% and 61%, respectively. Statistically significant correlations were observed between CEA and CYFRA 21‐1 responses and OR (P = .01 and P = .004, respectively). The median survival from response assessment (landmark analysis) was 9 months. In a univariate analysis, disease stage, performance status, baseline lactate dehydrogenase level (LDH), OR, CEA response, and CYFRA 21‐1 response were correlated significantly with survival. In particular, the median survival was 13 months for patients who had a CEA response and 11 months for patients who had a CYFRA 21‐1 response compared with 8 months and 6 months for patients who did not respond, respectively. In a multivariate analysis, performance status (P = .005), baseline LDH level (P = .02), CEA response (P = .03) and CYFRA 21‐1 response (P = .01) were confirmed as independent prognostic factors for survival.CONCLUSIONS.CEA and CYFRA 21‐1 responses appeared to be reliable surrogate markers of chemotherapy efficacy in patients with advanced NSCLC. Cancer 2006. © 2006 American Cancer Society.
Phase II study of intravenous TZT‐1027 in patients with advanced or metastatic soft‐tissue sarcomas with prior exposure to anthracycline‐based chemotherapy
Authors: Patel Shreyaskumar , Keohan Mary Louise , Saif M. Wasif , Rushing Daniel , Baez Luis , Feit Kevie , DeJager Robert , Anderson Sibyl 
Published: November 2006

AbstractBACKGROUND.TZT‐1027, a novel chemotherapeutic agent, is derived from dolastatin 10, and blocks cells during G2/M‐phase by interfering with microtubule assembly and stability. TZT‐1027 has exhibited potential cytotoxic activity in several human cancer cell lines (in vitro) and also demonstrated antitumor activity in human xenografts (in vivo). In addition, Phase I clinical investigations suggested activity in STS (soft‐tissue sarcoma).METHODS.Eligible patients were those who had histologic evidence of locally advanced or metastatic STS and who had received 1 prior treatment regimen with an anthracycline‐based chemotherapy for metastatic disease. Subjects received intravenous infusions of TZT‐1027 over 1 hour on Day 1 and Day 8 of each 21‐day treatment course. Efficacy was evaluated per Response Evaluation Criteria in Solid Tumors (RECIST) criteria.RESULTS.Twenty‐nine patients were enrolled and 28 patients received at least 1 course of study drug and were eligible for efficacy and safety evaluation. The median age of the patients was 48 years (range, 23–73 years) and the median baseline Eastern Cooperative Oncology Group (ECOG) performance status was 1 (range, 0–2). A total of 67 courses (range, 1–9 courses; median, 2 courses) of TZT‐1027 were administered. No patient in the study demonstrated an objective response to treatment. Of 6 patients (21.4%) who experienced disease stabilization, 1 continued to have stable disease for 9.3 months. The median time to tumor progression was 44 days (95% confidence interval [95% CI], 43.0–54.0) and the median survival was 178 days (95% CI, 134.0–317.0). The most commonly reported toxicities were neutropenia, fatigue, and constipation.CONCLUSIONS.TZT‐1027 was found to be safe and well tolerated, and the hematologic toxicities observed were consistent with preclinical toxicology and Phase I study findings. No confirmed responses were seen in the current study. Cancer 2006. © 2006 American Cancer Society.
Darbepoetin α for the treatment of anemia in patients with myelodysplastic syndromes
Authors: Giraldo Pilar , Nomdedeu Benet , Loscertales Javier , Requena Carmen , de Paz Raquel , Tormo Mar , Navarro Pilar , Benedit Patricia , Gasquet José Antonio ,   on behalf of the Aranesp in Myelodysplastic Syndromes (ARM) Study Group
Published: November 2006

AbstractBACKGROUND.Anemia occurs as a comorbidity in from 80% to 85% of patients with myelodysplastic syndromes (MDS): It causes fatigue, increases transfusion needs, and reduces quality of life. Darbepoetin α (DA) is an erythropoiesis‐stimulating protein (ESP) that is more highly glycosylated and has a longer half‐life relative to recombinant human erythropoietin (rHuEPO), thus, allowing less frequent administration, increased convenience, and better compliance.METHODS.This retrospective analysis included 81 patients with MDS who were enrolled at 9 Spanish centers and who received once‐weekly, subcutaneous DA (75–300 μg) for 16 weeks.RESULTS.Fifty‐five percent of all patients (38 of 69 evaluable patients) achieved responses; 30.4% of were major responses, and 24.6% were minor responses; 64.7% of rHuEPO‐naive patients and 45.7% rHuEPO‐treated patients responded; and 43.2% had received previous rHuEPO. Most responses (65.8%) occurred at or before Week 8. The median age at diagnosis was 70 years (range, 38–87 years), the median age at the initiation of DA treatment was 75 years (range, 39–91 years), and 56.8% of patients were women. The median time from last ESP dose to DA initiation was 16.8 weeks (range, 0.0–159.0 weeks; <1 week in 53.1% of patients). According to the French‐American‐British classification system (n = 81 patients), 39.5% had refractory anemia (RA), 46.9% had RA with ringed sideroblasts, 9.9% had RA with excess blasts (RAEB), 1.2% had RAEB in transformation, and 2.5% had chronic myelomonocytic leukemia. According to the International Prognostic Scoring System (n = 47 patients), 55.3% of patients were in the low‐risk group, and 36.2% of patients were in the intermediate‐1‐risk group. The median baseline hemoglobin level was 8.9 g/dL (range, 8.4–9.1 g/dL). The Starting DA dose was 75 μg per week in 3.7% of patients, 150 μg per week in 65.4% of patients, and 300 μg per week in 29.6% of patients (the dose was increased in 18.5% of patients and reduced in 9.9% of patients; median time to dose adjustment, 8 weeks). Five patients received granulocyte colony‐stimulating factors. No DA‐related adverse reactions occurred.CONCLUSIONS.In the current study, 55% of evaluable patients with MDS safely achieved an erythroid response. Cancer 2006. © 2006 American Cancer Society.
Population‐based study of renal cell carcinoma in children in Germany, 1980–2005
Authors: Selle Barbara , Furtwängler Rhoikos , Graf Norbert , Kaatsch Peter , Bruder Elisabeth , Leuschner Ivo 
Published: November 2006

AbstractBACKGROUND.Childhood renal cell carcinomas (RCCs) differ histologically and biologically from their adult counterparts. The characteristics of RCC‐affected children and their tumors, the influence of treatment, and outcome have so far not been studied in a nonselected, population‐based cohort.METHODS.A retrospective analysis was undertaken of RCC patients less than 16 years old reported to the German Childhood Cancer Registry and to the Kiel Paediatric Tumor Registry from 1980 to 2005.RESULTS.Forty‐nine RCC in children (24 boys, 25 girls) with a median age of 10.6 years were identified. In about every third child possibly RCC‐related underlying disorders (tuberous sclerosis, neuroblastoma, teratoma with chemotherapy, Saethre‐Chotzen syndrome, chronic renal failure) or related diseases in their family were found. The pathologic subtypes were papillary in 16 (33%), translocation type in 11 (22%), unclassified in 8 (16%), and rarely clear‐cell (n = 3) or others. Thirty‐four (69%) patients had localized RCC, 8 (16%) patients regional lymph node metastases, and 4 (8%) patients distant metastases. Event‐free survival and overall survival rates at 5 years were 96% for localized RCC, 69% and 75% for regional lymph node‐positive, 25% and 33% for distant metastatic RCC, respectively. Two of 4 patients with distant metastases received immunotherapy combined with chemotherapy and surgery, both are alive, 1 of them disease‐free for 6.9 years.CONCLUSIONS.Pediatric RCCs are predominantly localized diseases. Children with RCC frequently suffer underlying disorders. Survival rates in localized and regional lymph node‐positive cases are favorable. Because of the rarity of RCC in childhood, an international study is necessary. Cancer 2006. © 2006 American Cancer Society.